HIV Positive Clinical Trial
Official title:
Antioxidant Activity and Lipid Peroxidation Status in Patients HIV+ Supplemented With Microencapsulated of Red Pomegranate
Human immunodeficiency virus (HIV) infection continues to be a pandemic, Mexico has around 184,000 people infected by this virus. A common metabolic problem for these patients is oxidative stress (OS), which has been related with the progression of the disease and the presence of comorbidities. Pomegranate is a fruit rich in antioxidants, which potentially can inhibit or reduce deleterious metabolic compounds resulting from OS; however; it has never been tested in patients infected with HIV. The present project was done in patients HIV+ from state of Hidalgo in order to see the effects of microencapsulated red pomegranate juice (MRPJ) and ascorbic acid (AA) on antioxidant activity and lipid peroxidation both biomarkers of oxidative stress. Sixty subjects were recruited, 30 HIV positive (HIV+) and 30 HIV negative (HIV-). Three subgroups (n=10) were formed from each group: 1) supplemented with (1g/d) MRPJ; 2) supplemented with 1g/d AA; and 3) control group (unsupplemented). The intervention lasted 90 days and blood samples were taken four times: at the beginning and every 30 days. Antioxidant activity in the blood serum was measured by the DPPH (2,2-diphenyl-1-picrylhydrazyl) and ABTS + (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) methods while lipid peroxidation by malondialdehyde (MDA) levels which was measured by TBARS method. The baseline results showed a significant decrease of antioxidant activity in HIV+ groups compared to the HIV- groups, although there was no significant difference in lipid peroxidation, as measured by MDA assay levels. Several studies suggest that the reduction of antioxidant activity is a consequence of the infection and the antiretroviral treatment, although the organism tries to reestablish it unbalance it usually fails, thus (OS) is significant in these patients. The groups that received AA had antioxidant activity greater than the MRPJ treated. MRPJ treatment, however, the groups that received MRPJ had significantly reduced lipid peroxidation. Reduced lipid peroxidation could have more beneficial effects on HIV+ subjects since the reduction of markers of OS, such as lipid peroxidation, has been associated with reductions in the risk of death from HIV.
Since Patients HIV+ suffer oxidative stress, microencapsulated of red pomegranate juice will be evaluated for decreasing oxidative stress in HIV+ patients it will be compared with patients treated with ascorbic acid. The supplementation will take 90 days and blood samples were taken four times: at the beginning of the study and every 30 days thereafter. Antioxidant activity in the blood serum was measured by the DPPH and ABTS+ methods lipid peroxidation was measured as stress oxidative markers ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00639145 -
Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol
|
||
Completed |
NCT01152684 -
Complementary & Alternative Medicine Use in HIV+ Latinos in the US-Mexico Border
|
||
Completed |
NCT01957748 -
CCTG 594: Engagement and Retention in Care for HIV+
|
N/A | |
Completed |
NCT01818258 -
IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children
|
Phase 4 | |
Withdrawn |
NCT03660722 -
Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 Positive Subjects
|
N/A | |
Completed |
NCT01793467 -
Transplantation and the Use of Raltegravir in HIV-Infected Patients
|
N/A | |
Completed |
NCT02938377 -
Alcohol Research Consortium in HIV-Intervention Research Arm
|
Phase 4 | |
Completed |
NCT01898754 -
Oligonucleotide Ligation Assay (OLA) Resistance Study
|
N/A | |
Active, not recruiting |
NCT01365065 -
Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy
|
Phase 2 | |
Completed |
NCT00106795 -
Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS
|
N/A | |
Not yet recruiting |
NCT02404233 -
Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects
|
Phase 4 | |
Completed |
NCT01154543 -
Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes
|
N/A | |
Completed |
NCT01154556 -
RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice
|
N/A | |
Completed |
NCT00857350 -
The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
|
N/A | |
Recruiting |
NCT01875588 -
Thinking and Memory Problems in People With HIV
|
||
Completed |
NCT01941121 -
CCTG 593: Testing and Linkage to Care
|
N/A | |
Terminated |
NCT01904201 -
Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People
|
N/A | |
Enrolling by invitation |
NCT00941889 -
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
|
N/A | |
Completed |
NCT02935296 -
Integrated Treatment and Prevention for People Who Inject Drugs
|
Phase 3 | |
Completed |
NCT01536899 -
Medical Marijuana Use in HIV+ Patients Prospective Cohort Study
|